Oppenheimer raises Relay Therapeutics stock price target on triplet data By Investing.com

Oppenheimer raised Relay Therapeutics’ price target to $18 from $14 and reiterated an Outperform rating after zovegalisib triplet data showed a 44% overall response rate with no Grade 3 hyperglycemia or drug-drug interactions. The firm said the results strengthen the path to frontline development and shift focus to vascular anomalies data expected in the next few months. Other analysts also turned more constructive on the same trial results, with Raymond James lifting its target to $23 and H.C. Wainwright to $19.

Analysis

The market is starting to price zovegalisib less like a single-asset binary and more like a platform validation event. The important second-order effect is not the response rate itself, but the de-risking of combination tolerability: if the drug can be deployed in triplets without hyperglycemia or interaction issues, it broadens the commercial map from salvage niches into earlier-line regimens where the revenue multiple is materially higher. That changes how investors should think about the asset’s optionality into 2026, because the valuation step-up now depends more on dose/sequence optimization and trial execution than on basic target biology.

Consensus may still be underestimating how much competitive pressure this creates on adjacent PI3K-pathway programs. A mutant-selective profile with cleaner safety can force rivals to compete on efficacy alone, which is harder when discontinuation and management burden become part of the value proposition. The real winner here may be development-speed: if frontline design is now clearer, every quarter of accelerated enrollment matters because the market will re-rate the stock on the pathway to registrational clarity, not just on one readout.

The risk is that enthusiasm outruns durability. In biotech, early response data can support a sharp rerating, but if progression metrics or subgroup consistency disappoint over the next 3–9 months, the multiple can compress as quickly as it expanded. The next catalyst set is asymmetric: near-term vascular anomalies data can extend momentum, but the stock is vulnerable if investors conclude the current move already discounts the best-case sequencing of Phase 3 success and label expansion.

Key Decisions for Investors

• Stay long RLAY into the next 1-3 month catalyst window, but size as a catalyst trade rather than a fundamental core position; the setup favors further upward revision if vascular anomalies data confirms platform breadth.
• Use call spreads instead of outright stock for the next 3-6 months on RLAY to capture continued rerating while limiting downside if the market starts demanding durability proof.
• For biotech relative value, pair long RLAY vs. short a PI3K-pathway competitor with a less differentiated safety profile; the thesis is that cleaner triplet tolerability should win earlier-line adoption and earn a premium multiple.
• If already long, take partial profits into any post-data spike and hold a core position for 2026 readthroughs; the upside case improves materially only if frontline development advances without safety concessions.